Facing limited capital, an aggressive competitive environment and tight capital markets, biopharma companies are facing the same question: Do you build capabilities in house, or do you seek outside expertise and outsource around your core competencies? Once that decision has been made, how do the capital markets view those management plays when looking at a company’s development strategy? What financial impact do those decisions have? Biocom has invited experts in finance, service, and clinical development to address these questions. More information and online registration is here.